Ibrutinib combined with TGR-1202 in CLL and mantle cell lymphoma (MCL): preliminary results
Challenges with the identification of ALL subtypes
What is the rationale for novel combination therapies?
Niels van de Donk
Checkpoint inhibitors: parallel management of the disease and immune-related toxicities
Long-term follow-up: AML17 trial of ATO and ATRA vs the standard of care in APL